{'fraction_non_alphanumeric': 0.028149190710767064, 'fraction_numerical': 0.030260380014074596, 'mean_word_length': 4.9004149377593365, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cystatin C Intrapatient Variability in Children with Chronic Kidney Disease Is Less than Serum Creatinine

Qiagen Mini Prep Kits. Genotyping was performed with a LightCycler (Roche) with the FastStart DNA Master Hybridization Probe PCR method. The tacrolimus concentrations, as measured by both methods in CYP3A5 nonexpressors and expressors, are shown in panels A and B, respectively, of Fig. 1. The ratio immunoassay/chromatographic assay for each tacrolimus concentration was calculated, and the ratio for expressors and nonexpressors was compared by ANOVA. The mean ratios were 0.965 in the expressors and 1.01 in the nonexpressors. The mean difference in the ratios was 0.045 (95% confidence interval, 0.028 to 0.118; P 0.22, not significant). The study had a power of 80% to detect a difference in ratios of 0.11 and a power of 95% to detect a difference of 0.14 at a significance level of 5%. Our results demonstrate that CYP3A5 genotype does not affect tacrolimus measurements by the Abbott immunoassay. Thus, the genetic influence on the pharmacokinetics of tacrolimus is most likely related to a genotype-phenotype association, rather than an artifact resulting from the specificity of the immunoassay. Although the presence of metabolites has the potential to interfere with the Abbott immunoassay, we found a high degree of concordance between the 2 assays for expressors and nonexpressors of the CYP3A5 gene.